Skip to main content

Press releases 2014

2014-12-05
Moberg Pharma AB (OMX: MOB) today announced that it shipped opening orders of its new line extension, Kerasal Nail® Fungal Nail Repair, to CVS/pharmacy, the nation’s second largest drug chain. CVS is the first national drug chain to sell this new item, which is packaged and merchandised specifically for beauty shoppers.
2014-11-20
Moberg Pharma AB (OMX: MOB) announces that Jeff Vernimb has been appointed General Manager for its U.S. operations and a member of Moberg’s Management Team – effective from December 15, 2014. Jeff Vernimb brings more than 25 years of experience in consumer health products marketing and sales across multi-national and smaller entrepreneurial businesses.
2014-11-18
Moberg Pharma’s CEO Peter Wolpert will present at the Jefferies 2014 Global Healthcare Conference on Thursday November 20, 2014, at 4:20 pm. Mr. Wolpert will discuss the Q3 results and the company’s growth strategy, Moberg Pharma’s phase 2 assets, including MOB-015 for which the company in September reported positive phase 2 results and the recently started phase 2 trial of BUPI in oral mucositis.
2014-11-17
Moberg Pharma AB (OMX: MOB) announces that, effective as of today, George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012. Appointed by Altaris Capital Partners, George E. Aitken-Davies remains a member of the Nomination Committee of Moberg Pharma until the Annual General Meeting in May 2015.
2014-11-14
Moberg Pharma’s partner in Southeast Asia and China, Menarini APAC, has initiated the launch in Malaysia of Moberg Pharma’s prescription-free treatment for nail fungus. The product is launched under Moberg’s brand Emtrix®
2014-11-11
In accordance with the resolution of the Annual General Meeting on May 13, 2014, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 13.
2014-11-04
Moberg Pharma AB (OMX: MOB) announced that it entered into a services agreement with Emerson Healthcare, a division of  Emerson Group, who will provide certain logistical services and all order to cash functions for retailer and wholesaler customers in the U.S. Along with the outsourcing agreement, the companies are entering into a new Sales Representation Agreement with Emerson Group. The two agreements will result in significant savings in sales and administrative costs for Moberg.
2014-10-28
Moberg Pharma AB (OMX: MOB) announced that the first patient has been included in a randomized controlled phase II study with BUPI, a novel topical formulation for the treatment of oral pain. The aim is to confirm the promising results gained from several smaller pilot studies and to evaluate if bupivacaine formulated as a lozenge can be an effective, safe and patient friendly treatment of oral pain. The results are expected in the first half of 2015.
2014-09-17
Moberg Pharma AB (OMX: MOB) announces successful top-line results from a phase II study for MOB-015 in onychomycosis (nail fungus). The primary endpoint, mycological cure after 15 months, was achieved in 54% of the patients.
2014-08-28
Moberg Pharma AB (OMX:MOB) today announced that its head of U.S. operations, Steve Cagle, has announced his resignation. In order to secure a smooth transition, he will remain in his position until end of January 2015 at the latest.
2014-06-30
The number of shares and votes in Moberg Pharma AB (publ) has increased by 2,068,965 to 13,962,537 during June 2014. Therefore, there are in total 13,962,537 shares and votes in the company as of June 30th, 2014.
2014-06-18
Not for announcement, publication or distribution, directly or indirectly, in or into the U.S., Canada, Japan, Hong Kong, New Zealand, South Africa or Australia. 
2014-06-16
Moberg Pharma North America launches a new website for Domeboro® - www.Domebororelief.com
2014-05-28
Moberg Pharma AB (publ) (”Moberg Pharma” or the “company”, OMX:MOB) today announces that the company has completed a directed share issue of 2.1 million new shares, which brings SEK 60 million to the company before transaction costs.
2014-05-13
Moberg Pharma AB’s (“Company”) Annual General Meeting took place on Tuesday, May 13th, 2014 in the Company´s premises in Bromma.
2014-04-14
Moberg Pharma AB (OMX: MOB) announced that the company has entered into a definitive agreement with Oracain II Aps (Denmark) to acquire all assets and global rights to a novel and patent pending oral formulation of the proven substance bupivacaine, for the treatment of pain in the oral cavity. The initial target indication is pain management for patients suffering from oral mucositis during cancer therapy.
2014-04-14
Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”) are hereby convened to the Annual General Meeting on Tuesday, May 13, 2014 at 5:00 p.m. in the Company´s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma (Alviks torg), Sweden.
2014-03-24
Moberg Pharma AB (OMX: MOB) announces that the company this week starts shipping a new patent pending formulation of its market leading product Kerasal Nail™ to U.S. customers.
2014-02-20
ACQUISITION OF OTC PRODUCTS IN THE U.S. AND POSITIVE INTERIM RESULTS FOR MOB-015
2014-02-14
Moberg Pharma AB (OMX: MOB) today announced that A. Menarini Asia-Pacific Holdings Pte. Ltd, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Kerasal Nail™ in eight Southeast Asian countries.
2014-02-04
Moberg Pharma AB (OMX: MOB) today announced that Safeway has informed Moberg that it plans to add Moberg’s Kerasal Nail Fungal Nail Renewal Treatment and Kerasal Exfoliating Foot Moisturizing Ointment to its stores in March 2014. Moberg estimates distribution at approximately 900 stores. Safeway is an American supermarket chain; it is the second largest supermarket chain in North America, after The Kroger Company and has over 1,300 stores located throughout the western and central United States.
2014-01-31
Moberg Pharma AB (OMX: MOB) today announced that its partner Leosons International has received approval for Kerasal Nail™ in UAE and will start launch preparations immediately.  Moberg Pharma signed a distribution agreement with Leosons International in October 2013 for sixteen markets in the MENA region.